865 related articles for article (PubMed ID: 9390536)
1. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Fisher B; Dignam J; Wolmark N; DeCillis A; Emir B; Wickerham DL; Bryant J; Dimitrov NV; Abramson N; Atkins JN; Shibata H; Deschenes L; Margolese RG
J Natl Cancer Inst; 1997 Nov; 89(22):1673-82. PubMed ID: 9390536
[TBL] [Abstract][Full Text] [Related]
2. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
[TBL] [Abstract][Full Text] [Related]
3. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
4. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
[TBL] [Abstract][Full Text] [Related]
5. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
6. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; DeschĂȘnes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
[TBL] [Abstract][Full Text] [Related]
7. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
Fisher B; Jeong JH; Anderson S; Wolmark N
J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
Albain KS; Barlow WE; Ravdin PM; Farrar WB; Burton GV; Ketchel SJ; Cobau CD; Levine EG; Ingle JN; Pritchard KI; Lichter AS; Schneider DJ; Abeloff MD; Henderson IC; Muss HB; Green SJ; Lew D; Livingston RB; Martino S; Osborne CK;
Lancet; 2009 Dec; 374(9707):2055-2063. PubMed ID: 20004966
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23.
Land SR; Kopec JA; Yothers G; Anderson S; Day R; Tang G; Ganz PA; Fisher B; Wolmark N
Breast Cancer Res Treat; 2004 Jul; 86(2):153-64. PubMed ID: 15319567
[TBL] [Abstract][Full Text] [Related]
10. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
[TBL] [Abstract][Full Text] [Related]
11. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
International Breast Cancer Study Group
J Clin Oncol; 1997 Apr; 15(4):1385-94. PubMed ID: 9193330
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
[TBL] [Abstract][Full Text] [Related]
15. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
[TBL] [Abstract][Full Text] [Related]
16. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
Ejlertsen B; Jensen MB; Elversang J; Rasmussen BB; Andersson M; Andersen J; Nielsen DL; Cold S; Mouridsen HT
Eur J Cancer; 2013 Sep; 49(14):2986-94. PubMed ID: 23756360
[TBL] [Abstract][Full Text] [Related]
17. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
Tormey DC; Gray R; Falkson HC
J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.
Fisher B; Anderson S; Tan-Chiu E; Wolmark N; Wickerham DL; Fisher ER; Dimitrov NV; Atkins JN; Abramson N; Merajver S; Romond EH; Kardinal CG; Shibata HR; Margolese RG; Farrar WB
J Clin Oncol; 2001 Feb; 19(4):931-42. PubMed ID: 11181655
[TBL] [Abstract][Full Text] [Related]
19. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
[TBL] [Abstract][Full Text] [Related]
20. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.
Pinder SE; Murray S; Ellis IO; Trihia H; Elston CW; Gelber RD; Goldhirsch A; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Gusterson BA
Cancer; 1998 Oct; 83(8):1529-39. PubMed ID: 9781946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]